Cost–utility analyses of drug therapies in breast cancer: a systematic review
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10549-016-3924-7.pdf
Reference195 articles.
1. Wolff AC, Hammond MEH, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013. doi: 10.1200/JCO.2013.50.9984
2. Giordano SH, Temin S, Kirshner JJ et al (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2078–2099. doi: 10.1200/JCO.2013.54.0948
3. Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 32:2255–2269. doi: 10.1200/JCO.2013.54.2258
4. Partridge AH, Rumble RB, Carey LA et al (2014) Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:3307–3329. doi: 10.1200/JCO.2014.56.7479
5. Van Poznak C, Somerfield MR, Bast RC et al (2015) Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 33:2695–2704. doi: 10.1200/JCO.2015.61.1459
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China;BMC Public Health;2024-05-09
2. French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel versus gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients;Therapeutic Advances in Medical Oncology;2024-01
3. Breast cancer methodology for maximization of resources currently used in Mexican centers;Gaceta Mexicana de Oncolog�a;2023-10-30
4. Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature;JNCI Monographs;2022-07-01
5. Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments;Quality of Life Research;2022-05-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3